Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG MIX 50 50 PEN versus HUMALOG MIX 75 25 PEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG MIX 50 50 PEN versus HUMALOG MIX 75 25 PEN.
HUMALOG MIX 50/50 PEN vs HUMALOG MIX 75/25 PEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by binding to insulin receptors on liver, muscle, and adipose tissue, promoting glucose uptake and storage, and inhibiting hepatic glucose production.
Insulin analog with intermediate-acting insulin (insulin lispro protamine suspension) and rapid-acting insulin (insulin lispro). Binds to insulin receptors, activating glucose uptake, glycogen synthesis, and lipogenesis, while inhibiting gluconeogenesis and ketogenesis.
Subcutaneous injection, 0.5 to 1 unit/kg/day divided into two doses (before breakfast and before dinner), individualized based on blood glucose levels.
Subcutaneous injection. Individualized based on metabolic needs. Typical total daily insulin dose: 0.5-1 unit/kg/day divided, with Humalog Mix 75/25 given 15 minutes before meals. Starting dose: 0.2-0.3 unit/kg/day for type 1 diabetes; 0.3-0.5 unit/kg/day for type 2 diabetes. Administer twice daily: before breakfast and before dinner. Dose adjustments based on blood glucose monitoring.
None Documented
None Documented
Terminal half-life: 0.5-1.0 hour (insulin lispro); clinical context: short duration due to rapid clearance.
Insulin lispro protamine: 13-16 hours (intermediate component); Insulin lispro: 1-2 hours (rapid component). Clinical context: Steady state achieved after 2-4 days of dosing.
Renal: 75-80% as metabolites; hepatic: 20-25% via biliary elimination.
Renal: 30-80% (protamine-insulin complex clearance); Hepatic: 10-20% (degradation by insulinase); Fecal: <1%
Category C
Category C
Insulin Analog
Insulin Analog